TITLE

Lung cancer in HIV infected patients: facts, questions and challenges

AUTHOR(S)
Cadranel, J.; Garfield, D.; Lavolé, A.; Wislez, M.; Milleron, B.; Mayaud, C.
PUB. DATE
November 2006
SOURCE
Thorax;Nov2006, Vol. 61 Issue 11, p1000
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
AIDS related mortality has fallen sharply in industrialised countries since 1996 following the introduction of highly active antiretroviral therapy. This has been accompanied by an increase in the proportion of deaths attributable to non-AIDS defining solid tumours, especially lung cancer. The risk of developing lung cancer seems to be higher in HIV infected subjects than in the general population of the same age, partly because the former tend more frequently to be smokers and, especially, intravenous drug users. The carcinogenic role of the antiretroviral nucleoside drugs and their interaction with smoking needs to be examined. Interestingly, there is no clear relationship between the degree of immunosuppression and the risk of lung cancer, so the reason for the increased risk is unknown. The mean age of HIV infected patients at the time of lung cancer diagnosis is 45 years and most are symptomatic. Lung cancer is diagnosed when locally advanced or metastatic (stage III-IV) in 75–90% of cases, similar to patients with unknown HIV status. Adenocarcinoma is the most frequent histological type. The prognosis is worse in HIV infected patients than in the general lung cancer population. Efficacy and toxicity data for chemotherapy and radiation therapy are few and imprecise. Surgery remains the treatment of choice for localised disease in patients with adequate pulmonary function and general good health, regardless of immune status. Prospective clinical trials are needed to define the optimal detection and treatment strategies for lung cancer in HIV infected patients.
ACCESSION #
23259083

 

Related Articles

  • Use of Risk Equations for Predicting Disease Progression in HIV Infection. Mocroft, Amanda; Lundgren, Jens D. // Clinical Infectious Diseases;4/1/2009, Vol. 48 Issue 7, p951 

    The author reflects on the benefits of the proposed models to identify HIV-1-infected patients at short-term risk of AIDS or death in Asia. The author stated that there is an important distinction between models that predict the short-term risk of disease progression and those that predict the...

  • Lung cancer in HIV patients and their parents: A Danish cohort study. Engsig, Frederik N.; Kronborg, Gitte; Larsen, Carsten S.; Pedersen, Gitte; Pedersen, Court; Gerstoft, Jan; Obel, Niels // BMC Cancer;2011, Vol. 11 Issue 1, p272 

    Background: HIV patients are known to be at increased risk of lung cancer but the risk factors behind this are unclear. Methods: We estimated the cumulative incidence and relative risk of lung cancer in 1) a population of all Danish HIV patients identified from the Danish HIV Cohort Study (n =...

  • Is the CD4 Cell Percentage a Better Marker of Immuriosuppression than the Absolute CD4 Cell Count in HIV-Infected Patients with Cirrhosis? Bongiovanni, Marco; Gori, Andrea; Lepri, Alessandro Cozzi; Antinori, Andrea; de Luca, Andrea; Pagano, Gabriella; Chiodera, Alessandro; Puoti, Massimo; d'Arminio Monforte, Antonella // Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, p650 

    Recently, it was shown that cirrhotic patients without human immunodeficiency virus (HIV) infection had low CD4 cell counts and normal CD4 cell percentages, suggesting that, for HIV-infected persons, the CD4 cell percentage might be a more accurate marker of disease progression than the absolute...

  • Live and learn. Csatari, Jeffrey // Men's Health;Oct95, Vol. 10 Issue 8, p48 

    Presents possible reasons why eight percent of HIV-infected people do not develop any acquired immune deficiency syndrome (AIDS) symptoms. Immune response Nonprogressors; Protection from a person;s genetic makeup; Infection with a weaker strain of HIV; Opinion from Dr. Susan Buchbinder, chief...

  • Voucher Incentives Improve Linkage to and Retention in Care Among HIV-Infected Drug Users in Chennai, India. Solomon, Sunil Suhas; Srikrishnan, Aylur K.; Vasudevan, Canjeevaram K.; Anand, Santhanam; Kumar, Muniratnam Suresh; Balakrishnan, Pachamuthu; Mehta, Shruti H.; Solomon, Suniti; Lucas, Gregory M. // Clinical Infectious Diseases;Aug2014, Vol. 59 Issue 4, p589 

    Modest voucher incentives were associated with significantly better linkage to and retention in care but not with virologic suppression among human immunodeficiency virus (HIV)-infected drug users in Chennai, India, a population with high HIV disease burden and low access to antiretroviral...

  • Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor. Grant, Philip; Taylor, Jonathan; Cain, Pat; Short, William; Gallant, Joel; Farthing, Charles; Thal, Gary; Coakley, Eoin; Zolopa, Andrew // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, p680 

    When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HIV)--infected patients who were randomized to receive atazanavir or boosted atazanavir, compared...

  • Scottish AIDS.  // BMJ: British Medical Journal (International Edition);1/21/89, Vol. 298 Issue 6667, p141 

    Presents AIDS cases developments in Great Britain. Statistics on the increased population of death occurrence among infected patients; Examination of the relation of drug abuse on the development of the disease; Assessment of the hospital policies on HIV antibody injections.

  • AIDS Incidence and Mortality in a Hospital-Based Cohort of HIV-1–Seropositive Patients Receiving Highly Active Antiretroviral Therapy in São Paulo, Brazil. Casseb, Jorge; Fonseca, Luiz Augusto Marcondes; Veiga, Ana Paula Rocha; de Almeida, Alexandre; Bueno, Analice; Ferez, Antonio Carlos; Gonsalez, Claudio R.; Brigido, Luis F.M.; Mendonca, Marcelo; Rodrigues, Rosangela; Santos, Niraldo; Malacarne, Eunice; Ronchini, Karla O.M.; Zihlmann, Karina F.; Duarte, Alberto J.S. // AIDS Patient Care & STDs;Sep2003, Vol. 17 Issue 9, p447 

    Brazilian AIDS and HIV-1-seropositive patients have had free access to highly active antiretroviral therapy (HAART) since November 1996. Although secondary data based on official mortality statistics indicate a sharp decrease in AIDS mortality, few if any studies tried to estimate the prognosis...

  • The efficacy of a brief intervention to reduce alcohol misuse in patients with HIV in South Africa: study protocol for a randomized controlled trial. Huis in ¨t Veld, Diana; Skaal, Linda; Peltzer, Karl; Colebunders, Robert; Ndimande, John V.; Pengpid, Supa // Trials;2012, Vol. 13 Issue 1, p190 

    Background: Alcohol abuse comes with risks for increased morbidity and mortality among patients with HIV. This study aims to determine the prevalence of alcohol use and other risk factors in a sample of primary care patients with HIV in South Africa and to assess a brief intervention to reduce...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics